Homepage | RMD Open | A leading rheumatology journal from …
2024年10月10日 · RMD Open. is an open access, peer-reviewed rheumatology journal that publishes original research on rheumatic and musculoskeletal disorders and connective tissue diseases. RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including ...
Current Issue | RMD Open
Rheumatoid arthritis. Letter: Immune reactivity directed against the carbamylated fibrinogen α chain does not cross-react with citrullinated fibrinogen immunodominant peptides in patients with rheumatoid arthritis (10 October, 2024) openaccess icon. Pauline Brevet, Olivier Boyer, Olivier Vittecoq, Manuel Fréret.
Authors | RMD Open | A leading rheumatology journal from …
RMD Open is an open access journal and levies an Article Processing Charge (APC) of 2,275 GBP (exclusive of VAT for UK and EU authors). The APC for Letters is 1,140 GBP. There are no submission, colour or page charges. There is a 25% discount for articles where the corresponding author has reviewed for RMD Open within the previous 12 months. A 50% discount on the standard APC will apply to ...
Bimekizumab provided rapid improvements in patient-reported …
Objectives To assess impact of bimekizumab treatment on patient-reported outcomes and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA), using 16-week data from two phase 3 studies. Methods BE OPTIMAL ([NCT03895203][1]; biologic disease-modifying antirheumatic drug (bDMARD)-naïve) and BE COMPLETE ([NCT03896581][2]; tumour necrosis factor inhibitor ...
About | RMD Open | A leading rheumatology journal from EULAR …
RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to ...
Combining patient-reported outcome measures to screen for …
Objectives To investigate whether a combination of general health (Visual Analogue Scale (VAS)), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain (VAS/Numerical Rating Scale (NRS)), quality of life (EQ-5D), fatigue (VAS/NRS) and presenteeism (0%–100% productivity loss) could aid as a screening tool to detect active disease in patients with …
Rheumatoid arthritis treatment: the earlier the better to prevent …
The management of rheumatoid arthritis has undergone major advances in recent years, both in terms of the drugs armamentarium and therapeutic strategy. Treating disease to target, aiming at remission, through a tight control protocol is regarded as the standard of care. Reaching clinical and radiographic disease remission has therefore become an achievable goal. Increasing evidence has ...
Psoriatic arthritis - RMD Open
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA). Methods Post hoc analyses used data from DISCOVER-2 ([NCT03158285][1]) biologic/Janus-kinase inhibitor-naïve participants with active PsA (≥5 swollen/≥5 tender joints, C-reactive ...
Psoriatic arthritis - RMD Open
Objectives To evaluate the efficacy through 52 weeks of guselkumab, an interleukin 23-p19 subunit inhibitor, in subgroups of pooled psoriatic arthritis (PsA) patients from the DISCOVER-1 and DISCOVER-2 trials defined by baseline patient characteristics. Methods Adults with active PsA despite standard therapies were enrolled in DISCOVER-1 (≥3 swollen and ≥3 tender joints, C reactive protein ...
Table of contents | RMD Open
ManuelKussmann, MarkusObermueller, KathrinSpettel, StefanWinkler, DanielAletaha. Review: A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis (16 ...